Allarity Therapeutics, INC 8-K filings

Allarity Therapeutics engages Shareholder Intelligence Services, LLC to investigate potential illegal naked short selling and trading irregularities in its common stock.

Allarity Therapeutics announced the presentation of Phase 2 clinical data for stenoparib, showing potential clinical benefit in heavily pre-treated ovarian cancer patients, including those with platinum-resistant and refractory disease, at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting.

Allarity Therapeutics settles with the SEC regarding past disclosures about FDA interactions, paying a $2.5 million civil penalty and resolving all outstanding legal matters.

Allarity Therapeutics will conduct a Phase 2 trial, fully funded by the U.S. Veterans Administration, to evaluate stenoparib combined with temozolomide for recurrent Small Cell Lung Cancer.

Allarity Therapeutics' Board of Directors has authorized a share repurchase program of up to $5 million, signaling confidence in the company's future and commitment to shareholder value.

Allarity Therapeutics announces the dismissal of a securities class action lawsuit, allowing the company to focus on advancing stenoparib and its companion diagnostic.

Allarity Therapeutics announces a new Phase 2 clinical trial protocol to advance stenoparib, a dual PARP/Wnt inhibitor, towards FDA approval for advanced ovarian cancer patients.

Allarity Therapeutics announces the expansion of its Phase 2 clinical trial for stenoparib to accelerate its development as a personalized cancer treatment for advanced ovarian cancer.

Allarity Therapeutics has reached an agreement in principle with the SEC to settle an investigation regarding disclosures related to its FDA application for Dovitinib, involving a $2.5 million penalty and a cease-and-desist order.

Allarity Therapeutics reports extended treatment duration in its Phase 2 stenoparib trial, a strengthened cash position, and new revenue-generating laboratory services.

Allarity Therapeutics announced its third quarter 2024 financial results, highlighting a strong cash position, progress in stenoparib development, and new leadership appointments.

Allarity Therapeutics has received a formal notice from the European Patent Office of its intention to grant a patent for its Drug Response Predictor (DRP) companion diagnostic specific to stenoparib.

Allarity Therapeutics has regained compliance with Nasdaq's minimum bid price rule after its stock price closed above $1.00 for 20 consecutive trading days.

Allarity Therapeutics has appointed Jeremy R. Graff as President and Chief Development Officer, effective September 30, 2024, to lead clinical development programs.

Allarity Therapeutics announced that two patients in its Phase 2 ovarian cancer trial have exceeded one year on stenoparib therapy, demonstrating durable clinical benefit.

Allarity Therapeutics has increased its at-the-market offering to $50 million and appointed Alexander Epshinsky as its new Chief Financial Officer, effective September 12, 2024.

Allarity Therapeutics has amended its previous filing to correct the effective time of a 1-for-30 reverse stock split to 12:01 a.m. on September 11, 2024, and also increased the number of shares authorized for grant under its equity incentive plan.

Allarity Therapeutics has reduced its authorized shares and implemented a 1-for-30 reverse stock split after receiving shareholder approval at its annual meeting.

Allarity Therapeutics has successfully raised $3.15 million through a private placement of Series A Convertible Redeemable Preferred Stock and amended its license agreement with Eisai Inc., extending a critical clinical trial deadline.

Allarity Therapeutics reports a strengthened financial position with a $20 million cash balance, extending its runway into 2026, and a strategic focus on its lead drug candidate, stenoparib.

Allarity Therapeutics has received a Wells Notice from the SEC concerning disclosures related to FDA meetings about its Dovitinib NDA submitted in 2021.

Allarity Therapeutics has been granted a hearing before a Nasdaq panel to present its plan for regaining compliance with the minimum bid price rule.

Allarity Therapeutics announced that multiple patients in its Phase 2 trial of stenoparib for advanced recurrent ovarian cancer have remained on treatment for over 30 weeks, demonstrating continued clinical benefit.

Allarity Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1, and intends to appeal the decision.

Allarity Therapeutics has replaced its existing consultancy agreement with a new Management Services Agreement with Ljungaskog Consulting AB, effective June 1, 2024, outlining the terms of engagement for CEO Thomas H. Jensen.

Allarity Therapeutics has amended its previous 8-K filing to include additional information regarding the conclusion of its Phase 2 clinical trial of stenoparib, which showed promising results in ovarian cancer patients.

Allarity Therapeutics has increased its at-the-market offering to $30 million and regained compliance with Nasdaq's minimum stockholders' equity requirement.

Allarity Therapeutics announced positive results from its Phase 2 trial of stenoparib, regained compliance with Nasdaq listing requirements, and significantly improved its cash and equity balances.

Allarity Therapeutics has successfully simplified its capital structure through the conversion of all Series A Preferred Stock and 93% of outstanding warrants, including all variable-priced warrants, into common stock.

Allarity Therapeutics has surpassed the Nasdaq's minimum equity requirement of $2.5 million and will request the withdrawal of its Form S-1 registration statement.